Remove Clinical Supply Remove Contract Manufacturing Remove Licensing Remove Marketing
article thumbnail

Abiogen acquires EffRx to fortify bone disease portfolio

Pharmaceutical Technology

Alkindi is one of EffRx’s three marketed drugs. The company’s last deal included an exclusive license agreement with the Cardiff, UK-headquartered specialty pharmaceuticals company Diurnal group for the commercialisation of Efmody (hydrocortisone) in Switzerland.